# Unlocking personalized endometrial cancer treatment: the critical role of the BBIRE biobank in sample collection and distribution

**Authors:** V. Bruno, M. Betti, L. Ciuffreda, A. M. B. Arteni, M. Ferretti, F. Rossi, C. Accetta, C. Mandoj, V. Laquintana, F. De Nicola, S. Donzelli, S. Vaccarella, A. Di Maio, T. Mancuso, M. Haoui, M. Carosi, G. Cigliana, E. Pescarmona, M. Fanciulli, G. Piaggio, E. Vizza, M. Pallocca, G. Ciliberto, G. Blandino, S. Di Martino

PMC · DOI: 10.3389/fmolb.2026.1748347 · Frontiers in Molecular Biosciences · 2026-02-12

## TL;DR

The BBIRE biobank helps advance personalized endometrial cancer treatment by collecting and distributing high-quality samples linked to clinical data.

## Contribution

The BBIRE biobank is presented as a key resource for translational research through standardized sample management and multiomics integration.

## Key findings

- BBIRE manages 545 gynecological tumor samples, including 321 endometrial cancer samples, with strict protocols for quality and privacy.
- The biobank supports translational research by linking annotated samples with clinical data and enabling multiomics and organoid studies.
- Collaborative use of BBIRE accelerates biomarker discovery and personalized treatment strategies for endometrial cancer.

## Abstract

Endometrial cancer (EC) is the most common gynecological malignancy and the sixth most common cancer in women. Although it primarily affects women around or after menopause, an increasing number of cases are now being found in women of reproductive age. This shift highlights the need for fertility-sparing treatments and research.

The tumor biobank of the Regina Elena National Cancer Institute (BBIRE) has played a central role in EC research by simplifying the collection and distribution of high-quality samples linked to clinical data. BBIRE follows strict protocols and uses secure databases to protect patient privacy, meet regulations, and keep clinical information accurate. These steps help maintain sample quality and reduce errors before analysis.

This research highlights the importance of the BBIRE-tissue processing group in the coordinated management of 545 gynecological tumor samples, comprising 321 EC samples, underscoring its importance as a crucial instrument for translational research. The biobank supports a complete research process, from patient enrollment to molecular data analysis. Its flexible, standardized structure helps ensure reliable results in different research settings.

As a gynecologic oncology resource, BBIRE facilitates large-scale studies and collaboration among team researchers. This support is essential for identifying new biomarkers, tailoring treatments, and advancing precision medicine. The development of personalized care and improved outcomes for women with EC can be accelerated when work is performed collaboratively by surgeons, biobanks, and researchers.

The BBIRE Biobank is a game changer in cancer research that enables the integration of annotated samples, multiomics data, and organoid models to identify molecular drivers and accelerate personalized care.

## Linked entities

- **Diseases:** endometrial cancer (MONDO:0002447)

## Full-text entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, NOG (noggin) [NCBI Gene 9241] {aka SYM1, SYNS1, SYNS1A}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, OSGEP (O-sialoglycoprotein endopeptidase) [NCBI Gene 55644] {aka GAMOS3, GCPL1, KAE1, OSGEP1, PRSMG1, TCS3}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, VIM (vimentin) [NCBI Gene 7431]
- **Diseases:** breast cancer (MESH:D001943), endometrial, ovarian, and vulvar cancers (MESH:D054515), ovarian cancer (MESH:D010051), WSI (MESH:C564543), DIN (MESH:D000081042), melanomas (MESH:D008545), EC (MESH:D016889), adenocarcinomas (MESH:D000230), uterine cancer (MESH:D014594), Cancer (MESH:D009369), AD (MESH:D000544), gynecologic malignancies (MESH:D005833), PDOs (MESH:C536408), FD (MESH:D000795)
- **Chemicals:** Citrate (MESH:D019343), nicotinamide (MESH:D009536), CO2 (MESH:D002245), Nacetylcysteine (MESH:D000111), isopropanol (MESH:D019840), PBS (MESH:D007854), eosin (MESH:D004801), DMSO (MESH:D004121), GlutaMAX (MESH:C054122), ethanol (MESH:D000431), H&amp;E (MESH:D006371), paraffin (MESH:D010232), DMEM/F12 (-), carboplatin (MESH:D016190), HEPES (MESH:D006531), hematoxylin (MESH:D006416), N2 (MESH:D009584), EDTA (MESH:D004492), paclitaxel (MESH:D017239), ammonium chloride (MESH:D000643), xylene (MESH:D014992), isopentane (MESH:C067038)
- **Species:** Enterovirus C (no rank) [taxon 138950], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12935657/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12935657/full.md

## References

27 references — full list in the complete paper: https://tomesphere.com/paper/PMC12935657/full.md

---
Source: https://tomesphere.com/paper/PMC12935657